Skip to main content
SpringerLink
Log in

Systemic Therapy for Pancreatic Neuroendocrine Tumors

  • Review Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Pancreatic neuroendocrine tumors (PanNETs) account for approximately 2% of all pancreatic malignancies. Several systemic treatment options have been developed over the last four decades, ranging from cytotoxic chemotherapy and octreotide to newer targeted therapies like sunitinib, cabozantinib, and lenvatinib. Although surgery or liver-directed therapy remains cornerstone for management of metastatic PanNETs, however, they remain unfeasible in majority of cases. PanNETs behave differently than SI-NETs (small intestinal NET); the former is more aggressive and less responsive to somatostatin-based therapies. The optimal sequence of the systemic therapies for the advanced PanNETs depends mainly on the tumor burden, Ki-67 index, and the tempo of the disease. In the end, drawing from ENETS (European Neuroendocrine Tumor Society) and ESMO (European Society for Medical Oncology) guidelines, we propose a working algorithm for the management of advanced PanNETs, not amenable to surgery or liver-directed therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Couvelard A, Cazes A, Cros J (2023) Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: what the clinician should know. Best Pract Res Clin Endocrinol Metab 37:101795

    Article  CAS  PubMed  Google Scholar 

  2. Herr RR, Eble TE, Bergy ME, Jahnke HK (1959) Isolation and characterization of streptozotocin. Antibiot Annu 7:236–240

    PubMed  Google Scholar 

  3. Hijioka S et al (2019) Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. Cancer Chemother Pharmacol 83:43–52

    Article  CAS  PubMed  Google Scholar 

  4. Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194

    Article  CAS  PubMed  Google Scholar 

  5. Capdevila J et al (2022) Streptozotocin, 1982–2022: Forty years from the FDA’s approval to treat pancreatic neuroendocrine tumors. Neuroendocrinology 112:1155–1167

    Article  CAS  PubMed  Google Scholar 

  6. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523

    Article  CAS  PubMed  Google Scholar 

  7. ClewemarAntonodimitrakis P et al (2016) Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity. Neuroendocrinology 103:345–353

    Article  CAS  Google Scholar 

  8. Kouvaraki MA et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4710–4719

    Article  Google Scholar 

  9. Turner NC et al (2010) Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 102:1106–1112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. De Mestier L et al (2019) Comparison of temozolomide-capecitabine to 5-fluorouracile-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses. Neuroendocrinology 108:343–353

    Article  PubMed  Google Scholar 

  11. Kulke MH et al (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406

    Article  CAS  PubMed  Google Scholar 

  12. Chan JA et al (2012) Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30:2963–2968

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Strosberg JR et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268–275

    Article  CAS  PubMed  Google Scholar 

  14. Kunz PL et al (2023) Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol 41:1359–1369

    Article  CAS  PubMed  Google Scholar 

  15. Girot P et al (2022) Oxaliplatin and 5-fluorouracil in advanced well-differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the french group of endocrine tumors. Neuroendocrinology 112:537–546

    Article  CAS  PubMed  Google Scholar 

  16. Kunz PL et al (2016) Oxaliplatin-fluoropyrimidine chemotherapy plus bevacizumab in advanced neuroendocrine tumors. Pancreas 45:1394–1400

    Article  CAS  PubMed  Google Scholar 

  17. Al-Toubah T, Morse B, Pelle E, Strosberg J (2021) Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior capecitabine/temozolomide. Oncologist 26:115–119

    Article  CAS  PubMed  Google Scholar 

  18. Sorbye H et al (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24:152–160

    Article  CAS  PubMed  Google Scholar 

  19. Yao JC et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69–76

    Article  CAS  PubMed  Google Scholar 

  20. Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–514

    Article  CAS  PubMed  Google Scholar 

  22. Capdevila J et al (2021) Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509). J Clin Oncol 39:2304–2312

    Article  CAS  PubMed  Google Scholar 

  23. Testing cabozantinib in patients with advanced pancreatic neuroendocrine and carcinoid tumors - Tabular View - ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/record/NCT03375320. Accessed 25 Jan 2024

  24. Salazar R et al (2022) LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: the SEQTOR study (GETNE 1206). Ann Oncol 33(7):S1412. https://doi.org/10.1016/j.annonc.2022.08.044

  25. Grande E (2016) Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: common sense or low rationale? World J Clin Oncol 7:149

    Article  PubMed  PubMed Central  Google Scholar 

  26. Scarpa A et al (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543:65–71

    Article  ADS  CAS  PubMed  Google Scholar 

  27. Albertelli M et al (2021) Present and future of immunotherapy in neuroendocrine tumors. Rev Endocr Metab Disord 22(3):615–636

    Article  PubMed  PubMed Central  Google Scholar 

  28. Caplin ME et al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224–233

    Article  PubMed  Google Scholar 

  29. Wolin EM et al (2015) Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 9:5075–5086

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  30. Pavel M et al (2018) Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer 25:309–322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Pavel ME et al (2019) Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol 30:2010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Strosberg JR et al (2019) Pembrolizumab treatment of advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study. J Clin Oncol 37(4):190 https://doi.org/10.1200/JCO.2019.37.4_suppl.190

  33. Baudin E et al (2022) NEUROENDOCRINE TUMOURS 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177 lutetium-octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial. Ann Oncol 33(7):S954. https://doi.org/10.1016/j.annonc.2022.07.1013

  34. Halfdanarson TR et al (2022) Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors. 40:TPS514–TPS514. J Clin Oncol 40(4):S514. https://doi.org/10.1200/JCO.2022.40.4_suppl.TPS514

  35. Efficacy and safety of 177Lu-edotreotide PRRT in GEP-NET Patients - Full Text View - ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT03049189. Accessed 25 Jan 2024

Download references

Author information

Authors and Affiliations

  1. Dept. of Medical Oncology, HCG Cancer Center, Ahmedabad, India

    Viraj Lavingia & Shruti Gohel

  2. Department of Medical Oncology, Vedanta Medical Research Foundation - Balco Medical Centre, Raipur, India

    Bhawna Sirohi

Authors
  1. Viraj Lavingia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shruti Gohel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bhawna Sirohi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bhawna Sirohi.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lavingia, V., Gohel, S. & Sirohi, B. Systemic Therapy for Pancreatic Neuroendocrine Tumors. Indian J Surg Oncol (2024). https://doi.org/10.1007/s13193-024-01908-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13193-024-01908-y

Keywords

Search

Navigation